Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice

Pihl, Anne Finne; Feng, Shan; Offersgaard, Anna; Alzua, Garazi Peña; Augestad, Elias Honerød; Mathiesen, Christian Kjaerulff; Jensen, Tanja Bertelsen; Krarup, Henrik; Law, Mansun; Prentoe, Jannick; Christensen, Jan Pravsgaard; Bukh, Jens; Gottwein, Judith Margarete

Published in:
Journal of Hepatology

DOI:

Publication date:
2022

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice

Graphical abstract

Highlights

- Efficient production of inactivated whole virus antigen for HCV vaccine candidates.
- Whole inactivated HCV vaccines induce broadly neutralizing antibodies in mice.
- Among adjuvants, AddaVax, analogue of licensed MF-59, shows the highest immunogenicity.
- Modifications of HCV envelope proteins increase neutralization epitope exposure.
- HCV with modified and original envelope proteins has similar immunogenicity.

Authors

Anne Finne Pihl, Shan Feng, Anna Offersgaard, …, Jan Pravsgaard Christensen, Jens Bukh, Judith Margarete Gottwein

Correspondence

jgottwein@sund.ku.dk (J.M. Gottwein).

Lay summary

A vaccine against hepatitis C virus (HCV) is needed to prevent the estimated 2 million new infections and 400,000 deaths caused by this virus each year. We developed inactivated whole HCV vaccine candidates using adjuvants licensed for human use, which, following immunization of mice, induced antibodies that efficiently neutralized all HCV genotypes with recognized epidemiological importance. HCV variants with modified envelope proteins exhibited similar immunogenicity as the virus with the original envelope proteins.
Inactivated whole hepatitis C virus vaccine employing a licensed adjuvant elicits cross-genotype neutralizing antibodies in mice

Anne Finne Pihl, Shan Feng, Anna Offersgaard, Garazi Peña Alzua, Elias Honerød Augustad, Christian Kjaerullff Mathiesen, Tanja Bertelsen Jensen, Henrik Krarup, Mansun Law, Jannick Prentoe, Jan Pravsgaard Christensen, Jens Bukh, Judith Margarete Gottwein

1Copenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases, Copenhagen University Hospital – Amager and Hvidovre, and Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; 2Department of Molecular Diagnostics, Aalborg University Hospital and Clinical Institute, Aalborg University, Aalborg, Denmark; 3Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California, United States; 4Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Keywords: hepatitis C virus; hepatitis; neutralizing antibodies; HCV vaccine; whole viral particle vaccine; HCV inactivation; HCV downstream processing; adjuvant; envelope glycoprotein; hypervariable region; glycosylation.

Received 5 June 2021; received in revised form 26 November 2021; accepted 22 December 2021; available online 4 January 2022
© 2022 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Introduction
Worldwide ∼2 million acute HCV infections occur yearly, leading to chronic infection in ∼75% of cases.1 More than 70 million individuals are estimated to be chronically infected, resulting in ∼400,000 annual deaths, mostly due to cirrhosis and hepatocellular carcinoma.1 Given the asymptomatic nature of HCV infection prior to development of severe (and often irreversible) liver damage and the lack of screening programs, it is estimated that less than 20% of infections are diagnosed. Further, not all diagnosed individuals receive treatment with direct-acting antivirals, partly due to their high cost.1 Moreover, treatment does not protect against reinfection, can be associated with severe side effects in hepatitis B virus co-infected individuals, and does not always eliminate the risk of hepatocellular carcinoma following HCV clearance. Finally, observed emergence of antiviral resistance could compromise future treatment efficacy. Therefore, a prophylactic vaccine is essential to achieve the World Health Organization’s objectives for HCV elimination as a major public health threat.2

Ideally, a vaccine should protect against different HCV variants.3 Among the 8 reported major HCV genotypes, genotype 1–6 are epidemiologically significant. There are various subtypes. Genotypes and subtypes differ in ∼30% and ∼20% of their sequence, respectively, and show differential sensitivity to neutralizing antibodies (nAbs).4,9 The HCV envelope (E)
glycoproteins (gp) E1 and E2 are the main targets of nAbs. The highly variable 27 amino acid motif hypervariable region 1 (HVR1) at the E2 N-terminus mediates HCV evasion from nAbs; it acts as immunological decoy that induces nAbs, which are rendered inefficient due to mutational escape, and facilitates closed envelope protein conformational states, which restrict nAb access to conserved neutralization epitopes. Further, HCV envelope protein glycosylation induced closed envelope protein states that protect conserved epitopes. Thus, in vitro deletion of HVR1 and mutation of glycosylation sites increased HCV sensitivity to nAbs.

Protection immunity against HCV is achievable as ~25% of acute infections are cleared, likely by nAbs and T cells. In a vaccine setting, nAbs might be sufficient for protection, as most licensed viral vaccines protect by nAbs. Further, early development of nAbs was predictive of HCV clearance in humans and passive immunization with nAbs prevented HCV infection in chimpanzees. Moreover, nAbs induced by a recombinant gpE1/gpE2 vaccine had protective effects in chimpanzees. In contrast, a viral vector-based vaccine inducing HCV-specific T cells did not protect against chronic HCV infection in chimpanzees and humans.

In humans, the gpE1/gpE2 vaccine yielded robust nAbs in <50% of immunized individuals. Compared to such subunit vaccines, whole virus vaccines show superior immunogenicity owing to a more native envelope protein conformation, a broader epitope array and a denser epitope presentation. The development of a whole virus HCV vaccine only became feasible following the development of infectious cell culture systems for HCV production. However, proof of the immunogenicity of cell-culture-produced HCV was only obtained with non-licensed adjuvants. Additionally, it remains an unresolved question whether envelope protein modifications designed to expose conserved neutralization epitopes improve HCV immunogenicity in the context of a whole virus vaccine.

We aimed to develop inactivated HCV vaccine candidates employing adjuvants licensed for human use and to investigate their immunogenicity in mice. We evaluated the capacity of vaccine-induced antibodies to broadly neutralize cell-culture-infectious HCV genotype 1-6 recombinants. Finally, we evaluated the impact of envelope protein modifications on vaccine immunogenicity by deleting HVR1 and mutating a glycosylation site.

Materials and methods

HCV recombinants

Recombinants for vaccine production and/or neutralization assays were: (i) High titer HCV5aHi with modification of an O-linked glycosylation site in E2 (T385P) in comparison to the reference strain SA13 virus HCV5a differing from HCV5aHi by reversion of T385P to T385, and (ii) HCV5aHi(ΔHVR1), newly engineered by deletion of HVR1 from HCV5aHi. For neutralization assays, HCV with genotype 1-6 envelope gp were used.

HCV cell culture

Huh7.5 cells were maintained as described. Generation of HCV virus stocks and further cell-culture-adaptation of HCV5a-Hi(ΔHVR1) by serial passage are described in the supplementary materials and methods.

Production of HCV for vaccine generation

HCV-infected Huh7.5 cells were seeded in 10-layer cell factories (Advenex) and maintained in serum-free Advenex Expression Medium (ThermoFisher Scientific) during the HCV production phase. For details see the supplementary materials and methods.

Evaluation of HCV-infected cell cultures

Details regarding the evaluation of the percentage of HCV antigen-positive cells in infected cell cultures by immunostaining, as well as HCV infectivity, and core titers in culture supernatants, are provided in the supplementary materials and methods.

HCV sequencing

Sanger sequencing of the HCV sequence of DNA maxipreparations or of amplicons of the HCV RNA genome of cell-culture-derived HCV generated by reverse-transcription PCR was carried out at Macrogen Europe as described and as detailed in the supplementary materials and methods.

Immunization of mice

BALB/c mice (Taconic Farms, Denmark) were vaccinated with concentrated and inactivated HCV or EndoFitr™ Ovalbumin (Invivogen) formulated with aluminum hydroxide (Alum)+monophosphoryl lipid A (MPLA) (Invivogen), AdvaVax™ (Invivogen) or Freund’s adjuvant (Invivogen) according to Danish regulations, as specified in the supplementary materials and methods.

Mouse serum IgG purification and quantification

IgG was purified (Amicon® Pro Affinity Concentration Kit Protein G, Millipore), concentrated (Vivasin® 500, 30,000 molecular weight cut-off (MWCO), GE Lifesciences) and quantified (IgG (total) Mouse Uncoated ELISA Kit, ThermoFisher or Cedex Bio Analyzer, Roche) according to the manufacturers instructions and as specified in the supplementary materials and methods.

In vitro neutralization assays

Neutralization assays for characterization of HCV with envelope protein modifications were performed as described, using human monoclonal antibodies (mAbs: AR3A, AR4A) or human polyclonal IgG preparations (C2112 or H067®). Neutralization assays with purified mouse IgG were carried out in a smaller volume than assays for characterization of HCV. The E1/E2 sequence of viruses used in neutralization assays was sequence confirmed to be identical to the plasmid sequence. For details see the supplementary materials and methods.

E1/E2 complexes and soluble E2 (sE2) ELISA

Binding of mouse serum IgG to recombinantly expressed native HCV5a (strain SA13) E1/E2 complexes derived from cell lysates of transfected HEK293T cells or his-tag purified HCV5a SA13 sE2 derived from supernatant of transfected HEK293T cells was
evaluated by ELISA, as described in the supplementary materials and methods.

Results
Production of HCV vaccine antigen
HCV for immunizations was produced in Huh7.5 cells in 10-layer cell factories under serum-free conditions and processed using a multitest protocol. A representative production with the cell-culture-infectious HCV recombinant HCV5aHi34 (Fig. S1) is shown in Fig. 1A-E. Following UV inactivation, the HCV antigen was formulated with adjuvant and used for 4 subcutaneous immunizations of BALB/c mice at 3-week intervals (Fig. 1F).

Immunization of mice with an inactivated whole virus HCV vaccine formulated with Alum+MPLA elicited nAbs with limited efficacy
First, mice were immunized with inactivated HCV5aHi formulated with Alum+MPLA, licensed for human use. Following sacrifice, serum IgG was purified and tested for nAbs against homologous HCV5aHi, showing dose-dependent neutralization, however, with limited efficacy. The half maximal inhibitory concentration (IC50) ranged from 64 to 589 μg/ml (mean 313 μg/ml) for 4 animals, while for 2 animals 50% neutralization was not observed at 1,000 μg/ml, the highest IgG concentration used (Fig. 2A). Near complete neutralization was only observed for 1 animal, while 18–72% was achieved for the other animals at the highest IgG concentration. No HCV-specific nAbs were detected in control mice immunized with ovalbumin and Alum+MPLA (Fig. S2). Vaccine-induced IgG specifically bound to homologous E1/E2 complexes and less strongly to sE2 (Fig. S3). Immunization with HCV5aHi formulated with the widely used experimental Freund’s adjuvant induced slightly better nAb responses, with mean IC50 at 286 μg/ml IgG and mean maximum neutralization of 83% against HCV5aHi (Fig. S4).

Immunization of mice with an inactivated whole virus HCV vaccine formulated with AddaVax elicited potent cross-genotype nAb responses
Next, we immunized mice with inactivated HCV5aHi formulated with AddaVax, an analogue of MF-59; MF-59 is licensed for human use. IgG purified from 9 vaccinated animals neutralized homologous HCV5aHi at IC50 of 15-66 μg/ml (mean 36 μg/ml) and near complete neutralization at the highest IgG concentration (Fig. 2B). Thus, AddaVax showed superior efficacy, with mean IC50 more than 15-fold lower than that of the Alum+MPLA vaccination group (Fig. 2C). Further, mean neutralization at the highest IgG concentration was 97% vs. 61% for IgG induced by AddaVax vs. Alum+MPLA (Fig. 2D). Importantly, IgG pooled from these 9 animals efficiently cross-neutralized HCV genotypes 1-6 at IC50 of 14-192 μg/ml, with near complete neutralization at the highest IgG concentration (Fig. 2E). No HCV-specific nAbs were detected in control mice (Fig. S2). Further, IgG purified from pooled serum of these 9 animals after the 2nd and 3rd immunization neutralized HCV5aHi at IC50 of 50 and 76 μg/ml, respectively, and with near complete neutralization at the highest IgG concentration (Fig. 2F). Moreover, vaccine-induced IgG specifically bound to homologous E1/E2 complexes and sE2 individually (Fig. 3), showing stronger binding than IgG induced by Alum+MPLA (Fig. S3). IgG induced following 3 and 4 immunizations showed similar, concentration-dependent binding. Slightly lower binding was observed for IgG derived following 2 immunizations (Fig. 3).

HCV with modified envelope proteins showed differential sensitivity to nAbs
Deletion of HVR1 or mutation of glycosylation sites has been reported to influence the neutralization sensitivity of cell-culture-derived HCV, presumably by influencing exposure of neutralization epitopes.31–34 However, how such modifications influence immunogenicity in the context of a whole virus vaccine has not been studied. HCV5aHi harbored the E2 substitution T385P, which has been shown to increase neutralization sensitivity.34 To investigate the influence of T385P on immunogenicity, we produced HCV5aHi(T385) with the substitution reverted to T385,46 yielding 5.6 log10 focus-forming units (FFUs)/ml in pooled supernatant from cell factories. Further, to study the influence of HVR1 on immunogenicity we developed HCV5aHi(ΔHVR1) by deleting HVR1 from HCV5aHi and by further culture adaptation, carrying out 18 passages in Huh7.5 cells to compensate for fitness impairment. The resulting polyclonal virus had acquired 3 additional dominant substitutions based on Sanger sequencing: N532D and L735I in E2 as well as K1609R in non-structural protein 3 (amino acid positions are related to the polyprotein of the 1a H77 reference sequence (GenBank accession no. AF009606)) (Fig. S1). Pooled passage 20 supernatant from cell factories inoculated with a passage 19 seed stock yielded 5.8 log10 FFUs/ml.

We characterized neutralization sensitivity of HCV5aHi(T385), HCV5aHi(ΔHVR1) and HCV5aHi in comparison to the reference virus HCV5a with the original envelope protein sequence35 using well characterized human mAbs (AR3A45 and AR4A46) and human polyclonal IgG (C211 and H06) (Fig. 4A-D). In line with previous results, HCV5aHi showed 6- to 18-fold increased neutralization sensitivity compared to HCV5a34 (Fig. 4E and F). HCV5aHi(ΔHVR1) showed a similar (6- to 22-fold) increase in neutralization sensitivity. In contrast, HCV5aHi(T385), also harboring the original E2 sequence, showed similar neutralization sensitivity as HCV5a. Similar differences in neutralization profiles were observed for processed HCV5aHi, HCV5aHi(ΔHVR1) and HCV5aHi(T385) (Fig. S5).

HCV vaccine candidates with modified envelope proteins induced similar nAb responses in mice
To evaluate if differences in neutralization sensitivity affected immunogenicity, mice were immunized with HCV5aHi, HCV5aHi(ΔHVR1) and HCV5aHi(T385) equivalent to 7.5 log10 FFUs using AddaVax. First, we proved that serum IgG purified from each animal neutralized HCV5aHi with similar efficacy (Fig. 2B and S6). Then, for each group, IgG pools were generated and used to neutralize HCV5aHi, HCV5aHi(ΔHVR1), HCV5aHi(T385) and the HCV5a reference virus (Fig. 5A-D). In these assays, IC50 ranged from 17 to 654 μg/ml. The HCV5aHi IgG pool showed somewhat higher neutralization efficacy than the other pools with IC50 of 17, 267, 126 and 69 μg/ml against HCV5aHi, HCV5aHi(ΔHVR1), HCV5aHi(T385), HCV5aHi(ΔHVR1) and HCV5a, respectively. Further, the IgG pools neutralized HCV1a at IC50 of 14–143 μg/ml (Fig. 5E) and HCV3a at IC50 of 192–295 μg/ml (Fig. 5F), with HCV5aHi-induced IgG showing the highest efficacy. Finally, IgG pools showed similar concentration-dependent binding to E1/E2 complexes and sE2 (Fig. 6). Overall, while modifications of the envelope proteins did not have major effects on immunogenicity, we observed a trend
Fig. 1. Production and downstream processing of cell-culture-derived HCV. (A) Example of production of HCV5aHi in 1 cell factory yielding 5 harvests of 800 ml serum-free supernatant with the indicated infectivity titers. (B) Schematic overview of the downstream process. (C-E) Example of processing – 16i HCV5aHi-containing supernatant pooled from 4 cell factories. (C) HCV infectivity titers and volumes of material from specified process steps: clarification; TFF 1 and TFF 2; 3-cushion UC with collection of 3 fractions (F1, F2, F3) and F2 being processed further; TFF 3; gradient UC pool (pool of 3 fractions); size exclusion Sephadex chromatography (vaccine antigen, pool of 5 fractions). (D) HCV infectivity titers and buoyant densities for gradient UC fractions; fraction 7, 8 and 9 (striped bars) were pooled (gradient UC pool). (E) HCV infectivity titers and OD at 230 nm for size exclusion chromatography fractions; fractions 2-6 (striped bars) were pooled (vaccine antigen). (A, C, D, E) HCV infectivity titers are means of triplicates with SEM. (F) Timeline for animal experiments. FFUs, focus-forming units; OD, optical density; TFF, tangential flow filtration; UC, ultracentrifugation. (This figure appears in color on the web.)
towards superior induction of nAbs by the HCV5aHi virus antigen.

**Discussion**

We provide proof-of-concept for immunogenicity of a whole virus inactivated HCV vaccine employing an adjuvant analogue of MF-59, which is licensed for human use. Immunizations resulted in induction of potent antibodies broadly neutralizing all major HCV genotypes with recognized epidemiological importance. HCV envelope protein variants with deletion of HVR1 and mutation of a putative O-linked glycosylation site showed differential neutralization sensitivity but overall similar immunogenicity.

Broadly nAbs are associated with protection from chronic HCV infection. Our results suggest that induction of broadly nAbs by a single virus antigen is possible. This is in line with proof-of-concept findings in chronically HCV-infected patients and in humans immunized with the gpE1/gpE2 vaccine, where cross-nAb targeting conformational epitopes were elicited by single isolates. HCV5aHi vaccine-induced nAbs exhibited slight differences in efficacy against different HCV isolates, overall reflecting differences previously observed using other nAbs, such as the relatively low efficacy against the HCV3a
These observations are in line with the hypothesis that conformational epitopes targeted by potent cross-genotype neutralizing mAbs, such as AR3A and AR4A, are conserved among HCV isolates, and that different neutralization sensitivity is mainly caused by isolate-specific epitope protection by HVR1- and glycan-dependent closed envelope protein conformational states.4,7,12,51

The highest IgG concentrations used in vitro neutralization assays, yielding close to complete neutralization, were ~10-fold lower than mean IgG concentrations in human serum. IC50 were comparable to those achieved in previous immunogenicity studies using whole inactivated genotype 2a HCV, however, formulated with non-licensed adjuvants; in these studies cross-neutralization of genotype 1a/b and 3a was observed, while genotypes 4-6 were not tested.31,33 Moreover, IC50 were in the range of IC50 of IgG in chimpanzees protected from HCV challenge following vaccination with the gpE1/gpE2 vaccine, and at least comparable to that of IgG induced by vaccines based on sE2 in small animal models.14,52-54

Future development of an inactivated HCV vaccine candidate will be facilitated by development of optimized serum-free bioreactor-based upstream and downstream processes.38,40,55 Future immunogenicity studies should aim at defining an optimal immunization schedule and HCV antigen dose. For production of whole virus vaccines, amounts of viral particles required to achieve a given immune response are of interest. In this study, antigen doses were defined by infectious unit equivalents, as infectivity titrations were used to monitor viral processing, providing evidence for the presence of intact particles, and as reported by others.56,57 This might not allow for an optimal comparison of amounts of particles for viruses showing different specific infectivities. Therefore, we retrospectively determined amounts of HCV core and genome copies in vaccine preparations. This analysis suggested that 3- to 6-fold higher amounts of viral particles might have been contained in the HCV5aHi(DHVR1) vaccine compared to the HCV5aHi and HCV5aHi(T385) vaccines (Table S1). This could explain the slightly higher E1/E2 binding by HCV5aHi(DHVR1)-induced IgG compared to IgG induced by the other 2 viruses. Based on core determinations, vaccine doses used in this study were comparable to doses used in previous inactivated HCV vaccine studies.31,33 A future research focus should be establishment of assays to quantify the amount of HCV envelope proteins, being the main antigenic proteins, in vaccine preparations.

An important achievement of our study is the development of a whole inactivated HCV vaccine candidate employing an analogue of a licensed adjuvant, facilitating its use in humans. In line with previous findings, MF-59 analogue AddaVax, also used in the gpE1/gpE2 vaccine, was superior in inducing binding Abs and nAbs compared to Alum used in most human vaccines and the experimental golden standard Freunds adjuvant.56,58 Further, whole inactivated genotype 2a HCV formulated with Alum yielded nAbs showing <20% neutralization.59 Nevertheless, comparatively high neutralization sensitivity of our vaccine antigens might have contributed to comparatively high immunogenicity. Thus, compared to the genotype 2a (isolate J6) HCV, HCV5aHi showed at least 200-fold higher sensitivity to the human antibodies used for characterization of HCV neutralization sensitivity (unpublished results).12

For other viruses, increased neutralization epitope exposure resulted in enhanced induction of nAbs following vaccination.59-61 According to assays applied in this study, increased HCV neutralization epitope exposure mediated by deletion of HVR1 did not result in increased immunogenicity, while modification of an O-linked glycosylation site in HCV5aHi resulted in somewhat increased induction of nAbs. While this question had not been addressed using whole HCV vaccines that would be expected to show close to native envelope conformations, similar findings were reported using envelope protein subunit vaccines. Thus, gpE1/gpE2 heterodimers or sE2 without HVRI, with or without an additional modification of a glycosylation site, enzymatically deglycosylated sE2, or insect cell produced sE2 showed no or slightly increased immunogenicity. Somewhat increased immunogenicity was observed for sE2 lacking all 3 variable regions.33

Future vaccine studies with HCV showing greater differences in neutralization sensitivity than the viruses used in this study might further clarify the potential of envelope protein engineering to increase immunogenicity. Compared to the reference virus HCV5a, both HCV5aHi and HCV5aHi(DHVR1) showed up to ~20-fold increased neutralization sensitivity,
while for other HCV recombinants, HVR1 deletion and modifications of glycosylation sites increased neutralization sensitivity by up to 5 orders of magnitude. This phenomenon is likely explained by the inherent high neutralization sensitivity of the HCV5a (strain SA13) reference virus, suggesting a predominantly open envelope protein conformational state with relatively high epitope exposure, which could only be somewhat increased by envelope modifications.

**Fig. 4.** HCV with different envelope proteins showed differential sensitivity to neutralizing antibodies. HCV5a, HCV5aHi(T385), HCV5aHi and HCV5a-Hi(ΔHVR1) were used in neutralization assays with human monoclonal antibodies – (A) AR3A and (B) AR4A – and human polyclonal IgG (C) C211 and (D) H06. Datapoints are means of triplicates with SEM. (E) IC50 from experiments (A-D). (F) Fold differences in IC50 against specified viruses in comparison to HCV5a (left) or HCV5aHi(T385) (right) shown in log2 radar plots. HVR1, hypervariable region 1; IC50, half maximal inhibitory concentration.
In conclusion, using an analogue of the licensed adjuvant MF-59 and whole inactivated cell-culture-derived HCV, we have developed an attractive HCV vaccine approach for further preclinical development. While a recently tested immunogenic T cell-based vaccine did not protect against chronic HCV infection in a phase I/II study, we here describe a vaccine platform...
inducing potent nAbs. In the future, following optimization of the vaccine preparation processes, clinical studies will be needed to elucidate if this vaccine approach will confer protection against chronic HCV infection.

**Abbreviations**

Alum, aluminium hydroxide; E1, HCV envelope glycoprotein E1; E2, HCV envelope glycoprotein E2; E1/E2, HCV envelope glycoprotein heterodimer; FFUs, focus-forming units; gp, glycoprotein; HCV, hepatitis C virus; HVR1, hypervariable region 1; IC50, half maximal inhibitory concentration; mAbs, monoclonal antibodies; MPLA, monophosphoryl lipid A; nAbs, neutralizing antibodies; sE2, soluble HCV envelope glycoprotein E2.

**Financial support**

This work was supported by PhD stipends and bonuses from the Candys Foundation (AFP, AO, EHA, JB, JMG) and from the University of Copenhagen (AFP, AO, GPA, EHA, CKM, TBJ, JB, JMG), grants from the Novo Nordisk Foundation (JB, JMG), The Danish Cancer Society (JB), Independent Research Fund Denmark (DIFF) - Medical Sciences (JB, JMG), Innovation Fund Denmark (JMG), The Lundbeck Foundation (JP, JB), The Region H Foundation (JB, JMG), The Toyota Foundation (JMG), Hvidovre Hospital Research Foundation (AFP, JMG) and The Læge Sofus Carl Emil Friis og Hustru Olga Doris Friis’ Foundation (JMG). ML is partly funded by NIH grants AI079031 and AI123861.

**Conflict of interest**

The authors declare no conflicts of interest that pertain to this work.

Please refer to the accompanying ICMJE disclosure forms for further details.

**Author contributions**

AFP, SF, AO, JPC, JB and JG designed the study. AFP, SF, AO, GPA, EHA, CKM, TBJ, HK and JPC performed the experiments. AFP, SF, AO, GPA, EHA, CKM, TBJ, ML, JP, JPC, JB and JMG analyzed and interpreted the data. AFP and JMG wrote the manuscript. JP, JPC, JB and JMG supervised the study. All authors reviewed the manuscript.

**Data availability statement**

All data needed to evaluate the conclusions in the paper are present in the paper and/or the supplementary information.

**Acknowledgements**

General: We thank Lotte Mikkelsen, Lubna Ghanem, Pia Pedersen and Anna-Louise Sørensen (Copenhagen University Hospital – Amager and Hvidovre, Copenhagen, Denmark) as well as Erick Giang (The Scripps Research Institute, USA) for laboratory assistance, Bjarne Ø. Lindhardt (Copenhagen University Hospital – Amager and Hvidovre, Copenhagen, Denmark) and Carsten Geisler (University of Copenhagen, Denmark) for their support. We thank Michael W. Wolff (University of Applied Sciences, Giessen, Germany) for helpful discussions and Charles M. Rice (The Rockefeller Center, USA) and Arvind H. Patel (University of Glasgow, UK) for reagents.

**Supplementary data**

Supplementary data to this article can be found online at https://doi.org/10.1016/j.jhep.2021.12.026.

**References**

*Author names in bold designate shared co-first authorship*


